March 12, 2013 – Oregon

Change to Antibiotic Susceptibility Testing Results

WHAT’S NEW?
Effective Tuesday, March 19, 2013, PeaceHealth Laboratories will implement new instrumentation to perform identification and susceptibility testing of bacteria.

This change will:
- Improve turnaround time
- Enable the adoption of recommended guidelines to lower the breakpoints for cephalosporins and carbapenems used to treat Gram-negative bacilli. This will eliminate the need for supplementary, extended spectrum beta-lactamase (ESBL) testing.

WHAT STAYS THE SAME?
Although the new instrumentation necessitates changes to the antibiotics routinely reported, many of the antibiotics previously reported will remain the same. In addition, some supplementary antibiotic testing will become available (see table below).

QUESTIONS?
Judy January, MT(ASCP)
Senior Clinical Scientist, Microbiology
☎ 541-687-2134 ext. 8466
☎ 800-826-3616 ext. 8466
jjanuary@peacehealthlabs.org

Robert Liao, PhD, D(ABMM)
Director, Microbiology and Molecular Diagnostics
☎ 541-687-2134 ext. 4798
☎ 800-826-3616 ext. 4798
rliao@peacehealthlabs.org

<table>
<thead>
<tr>
<th>SUMMARY OF ANTIBIOTIC REPORTING CHANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Action</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>Added</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Removed</td>
</tr>
</tbody>
</table>

Addendum on next page
ANTIBIOTIC SUSCEPTIBILITY TESTING LIMITATIONS

Gram-negative bacteria testing limitations:

- Amikacin will not report for *Acinetobacter baumanii*.
- Augmentin will not report for *Providencia* spp.
- Ampicillin will not report for *Citrobacter* spp., *Enterobacter* spp., *Pantoea* spp., *Serratia* spp., or *Cronobacter sakazakii*.
- Piperacillin/tazobactam will not report for *Serratia marscens*.

Gram-negative bacteria limitations due to FDA indications for use:

- Ertapenem will only report for *Escherichia coli*, *Klebsiella pneumoniae*, *Citrobacter freundii*, *Citrobacter koseri*, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Morganella morganii*, *Proteus mirabilis*, *Proteus vulgaris*, and *Serratia marscens*.
- Levofloxacin will only report for *Acinetobacter baumanii*, *Acinetobacter lwofii*, *Citrobacter freundii*, *Citrobacter koseri*, *Cronobacter sakazakii*, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Enterobacter sakazakii*, *Escherichia coli*, *Klebsiella oxytoca*, *Klebsiella pneumoniae*, *Pantoea agglomerans*, *Proteus mirabilis*, *Proteus vulgaris*, *Providencia rettgeri*, *Providencia stuartii*, *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*, and *Serratia marscens*.
- Meropenem will only report for *Acinetobacter spp.*, *Aeromonas hydrophila*, *Citrobacter diversus*, *Citrobacter freundii*, *Enterobacter cloacae*, *Escherichia coli*, *Hafnia alvei*, *Klebsiella oxytoca*, *Klebsiella pneumoniae*, *Morganella morganii*, *Pasteurella multocida*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Salmonella spp.*, *Serratia marcescens* and *Shigella* spp.
- Piperacillin/tazobactam will only report for *Acinetobacter baumanii*, *Citrobacter koseri*, *Escherichia coli*, *Klebsiella pneumoniae*, *Morganella morganii*, *Proteus mirabilis*, *Proteus vulgaris*, *Providencia rettgeri*, *Providencia stuartii*, *Pseudomonas aeruginosa*, and *Salmonella enterica*.
- Trimethoprim/sulfamethoxazole will only report for *Cronobacter sakazakii*, *Escherichia coli*, *Klebsiella spp.*, *Enterobacter spp.*, *Morganella morganii*, *Proteus mirabilis*, *Proteus vulgaris*, *Shigella sonnei* and *Shigella flexneri*.

continued on next page
Staphylococcus spp. testing limitations due to FDA indications for use:

- Daptomycin will only report for *Staphylococcus aureus*.
- Linezolid will only report for *Staphylococcus aureus*, *Staphylococcus epidermidis* and *Staphylococcus haemolyticus*.
- Quinupristin/Dalfopristin (Synercid) will only report for methicillin-susceptible *Staphylococcus aureus* and *Staphylococcus epidermidis*.
- Trimethoprim/sulfamethoxazole will only report for *Staphylococcus aureus*.

Enterococcus spp. testing limitations due to FDA indications for use:

- Daptomycin will only report for vancomycin resistant strains of *Enterococcus faecalis*.
- Linezolid will only report for *Enterococcus faecium* and *Enterococcus faecalis*. 